MRK1

114.95

-0.39%↓

SHL.DE

46.57

+0.34%↑

ARGX

515.4

+0.98%↑

FRE

44.24

+0.07%↑

ONC.US

254.35

-0.88%↓

MRK1

114.95

-0.39%↓

SHL.DE

46.57

+0.34%↑

ARGX

515.4

+0.98%↑

FRE

44.24

+0.07%↑

ONC.US

254.35

-0.88%↓

MRK1

114.95

-0.39%↓

SHL.DE

46.57

+0.34%↑

ARGX

515.4

+0.98%↑

FRE

44.24

+0.07%↑

ONC.US

254.35

-0.88%↓

MRK1

114.95

-0.39%↓

SHL.DE

46.57

+0.34%↑

ARGX

515.4

+0.98%↑

FRE

44.24

+0.07%↑

ONC.US

254.35

-0.88%↓

MRK1

114.95

-0.39%↓

SHL.DE

46.57

+0.34%↑

ARGX

515.4

+0.98%↑

FRE

44.24

+0.07%↑

ONC.US

254.35

-0.88%↓

Search

Sanofi SA

Uždarymo kaina

SektoriusSveikatos priežiūra

88.23 0.88

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

87.47

Max

88.42

Pagrindiniai rodikliai

By Trading Economics

Pajamos

1.4B

1.9B

Pardavimai

3B

11B

P/E

Sektoriaus vid.

17.216

51.198

Pelnas, tenkantis vienai akcijai

1.79

Dividendų pajamingumas

4.48

Pelno marža

17.65

Darbuotojai

82,878

EBITDA

2.2B

2.8B

Rekomendacijos

By TipRanks

Rekomendacijos

Pirkti

12 mėnesių prognozė

+31.16% upside

Dividendai

By Dow Jones

Dividendų pajamingumas

Sektoriaus vid.

4.48%

2.40%

Kitas uždarbis

2025-07-31

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

-19B

111B

Ankstesnė atidarymo kaina

87.35

Ankstesnė uždarymo kaina

88.23

Naujienos nuotaikos

By Acuity

39%

61%

136 / 380 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Very Strong Bearish Evidence

Sanofi SA Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-06-02 16:05; UTC

Pagrindinės rinkos jėgos

Nurix Therapeutics Stock Climbs as Sanofi Extends License for STAT6

2025-06-02 09:17; UTC

Įsigijimai, susijungimai, perėmimai

Sanofi to Buy Blueprint Medicines for Up to $9.5 Billion in Boost to Pipeline -- Update

2025-06-02 05:31; UTC

Įsigijimai, susijungimai, perėmimai

Sanofi to Acquire Blueprint Medicines for Up to $9.5 Billion

2025-05-22 12:02; UTC

Pagrindinės rinkos jėgos
Įsigijimai, susijungimai, perėmimai

Vigil Neuroscience Shares Surge After Sanofi's Planned Acquisition

2025-05-22 00:06; UTC

Įsigijimai, susijungimai, perėmimai

Sanofi to Buy Vigil Neuroscience for About $470 Million

2025-06-02 13:50; UTC

Uždarbis
Įsigijimai, susijungimai, perėmimai

Blueprint Medicines Soars 26% on $9.5 Billion Buyout. Why This Drug Is Key to the Deal. -- Barrons.com

2025-06-02 12:33; UTC

Rinkos pokalbiai
Įsigijimai, susijungimai, perėmimai

Sanofi Portfolio Approach Awaits Proof of Improvement -- Market Talk

2025-06-02 10:50; UTC

Įsigijimai, susijungimai, perėmimai

Blueprint Medicines Soars 27% on $9.5 Billion Buyout. Why This Drug Is Key to the Deal. -- Barrons.com

2025-06-02 10:05; UTC

Rinkos pokalbiai
Įsigijimai, susijungimai, perėmimai

Sanofi's Blueprint Deal Seems Like Good Fit -- Market Talk

2025-06-02 05:06; UTC

Įsigijimai, susijungimai, perėmimai

Sanofi: Total Equity Value, Including Potential CVR Payments, Represents About $9.5B on Fully Diluted Basis

2025-06-02 05:06; UTC

Įsigijimai, susijungimai, perėmimai

Sanofi: Blueprint Shareholders Also Will Receive One Non-Tradeable Contingent Value Right

2025-06-02 05:05; UTC

Įsigijimai, susijungimai, perėmimai

Sanofi: Deal Represents an Equity Value of Approximately $9.1B

2025-06-02 05:05; UTC

Įsigijimai, susijungimai, perėmimai

Sanofi Will Pay $129.00 Per Share in Cash at Closing

2025-06-02 05:04; UTC

Įsigijimai, susijungimai, perėmimai

Sanofi: Blueprint Is Expected to Enhance Sanofi's Growing Immunology Pipeline

2025-06-02 05:04; UTC

Įsigijimai, susijungimai, perėmimai

Sanofi: Acquisition Includes Rare Immunology Disease Medicine, Ayvakit/Ayvakyt

2025-06-02 05:03; UTC

Įsigijimai, susijungimai, perėmimai

Sanofi to Buy Blueprint Medicines Corporation

2025-06-02 05:02; UTC

Įsigijimai, susijungimai, perėmimai

Sanofi to Acquire Blueprint Medicines Corporation

2025-05-30 08:58; UTC

Karštos akcijos

Stocks to Watch Friday: Dell, Marvell, Gap, Ulta -- WSJ

2025-05-30 08:56; UTC

Rinkos pokalbiai

Sanofi, Regeneron Hit by Trial Disappointment -- Market Talk

2025-05-27 05:03; UTC

Įsigijimai, susijungimai, perėmimai

Sanofi Closes Acquisition of DR-0201 From Dren Bio

2025-05-27 05:00; UTC

Įsigijimai, susijungimai, perėmimai

Press Release: Sanofi Completes Acquisition Of DR-0201 >SAN.FR

2025-05-21 23:33; UTC

Įsigijimai, susijungimai, perėmimai

Vigil Neuroscience: Iluzanebart Return to Licensor Amgen to Occur Prior to Closing of Sanofi Deal

2025-05-21 23:32; UTC

Įsigijimai, susijungimai, perėmimai

Vigil Neuroscience Sees Sanofi Deal Strengthening Development Path for Oral Small Molecule TREM2 Agonist Program

2025-05-21 23:32; UTC

Įsigijimai, susijungimai, perėmimai

Vigil Neuroscience: Shareholders to Get Up to $10 a Share in Sanofi Deal >SAN.FR VIGL

2025-05-21 23:23; UTC

Įsigijimai, susijungimai, perėmimai

Sanofi: VGL101, Vigil's Second Molecule Program, Isn't Being Acquired

2025-05-21 23:22; UTC

Įsigijimai, susijungimai, perėmimai

Sanofi Sees No Effect From Vigil Deal on 2025 Outlook >SAN.FR

2025-05-21 23:20; UTC

Įsigijimai, susijungimai, perėmimai

Sanofi: Vigil Deal Enhances Early-Stage Pipeline, Includes VG-3927, Which Will Be Evaluated in Alzheimer's Disease Study

2025-05-21 23:18; UTC

Įsigijimai, susijungimai, perėmimai

Sanofi to Buy Vigil Neuroscience for $8 a Share at Closing >SAN.FR VIGL

2025-05-19 11:01; UTC

Rinkos pokalbiai

Diversified Exposure to European Banks Is Required -- Market Talk

2025-05-15 11:04; UTC

Rinkos pokalbiai
Uždarbis

Spanish, Italian Banks Have Less Upside After Strong Run -- Market Talk

Akcijų palyginimas

Kainos pokytis

Sanofi SA Prognozė

Kainos tikslas

By TipRanks

31.16% į viršų

12 mėnesių prognozė

Vidutinis 114.266 EUR  31.16%

Aukščiausias 127 EUR

Žemiausias 95 EUR

Remiantis 17 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Sanofi SA kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

17 ratings

12

Pirkti

5

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

91.3 / 96.1Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Very Strong Bearish Evidence

Vidutinės trukmės periodas

Strong Bearish Evidence

Ilgalaikis periodas

Bullish Evidence

Rinkos nuotaikos

By Acuity

136 / 380 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Bulių rinkos įrodymas

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Aukščiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Sanofi SA

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. In addition, it offers poliomyelitis, pertussis, and hib pediatric vaccines; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, cholera, yellow fever, and rabies vaccines. The company also provides cough, cold, and flu, allergy, and pain care products, as well as physical, mental, and digestive wellness products; and offers products for itching, hydration, aging, cracking, overnight, and specialty skincare needs like eczema. Further, it has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301, a treatment for alpha-synucleinopathies; Blackstone Life Sciences to develop pivotal studies and clinical development program; and Seagen Inc. to design, develop, and commercialize antibody-drug conjugates for cancer. Additionally, the company has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Skyhawk Therapeutics, Inc to discover and develop novel small molecules; and Adagene Inc., for the discovery and development of antibody-based therapies. It also has collaborations with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.